1. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2021) Authors: Kosiborod, Mikhail N; Esterline, Russell; Furtado, Remo H M; Oscarsson, Jan; Gasparyan, Samvel B; Koch, Gary G; Martinez, Felipe; Mukhtar, Omar; Verma, Subodh; Chopra, Vijay; Buenconsejo, Joan; Langkilde, Anna Maria; Ambery, Philip; Tang, Fengming; Gosch, Kensey; Windsor, Sheryl L; Akin, Emily E;... Journal: Lancet Issue: Volume 9:Issue 9(2021) Page Start: 586 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗